TY - JOUR
T1 - Validation of Dermaphot® for the assessment of steroid-induced skin atrophy
AU - Hofmann, M.
AU - Salgo, R.
AU - Aschoff, R.
AU - Luger, T. A.
AU - Meurer, M.
AU - Bräutigam, M.
AU - Thaci, Diamant
N1 - Funding Information:
Acknowledgments This was an investigator-initiated clinical trial. The study protocol and study design were proposed by Matthias Hofmann and Diamant Thaci. The authors thank C. Joisten for technical assistance. This work was supported by the LOEWE Prä-bionik network of the state of Hesse to M.H. and a GCP grant from the Ethics Committee of the Faculty of Medicine of the Goethe University to DT. Pimecrolimus 1 % cream was kindly provided by Novartis Pharma GmbH, Nuremberg, Germany.
PY - 2013/4
Y1 - 2013/4
N2 - Currently, there are no accurate and simple methods available to measure this risk of atrophy in patients treated with topical glucocorticosteroids. In the present clinical trial, we validated a new score (Dermaphot® score) to assess the atrophogenic potential of glucocorticosteroids. 36 healthy adult volunteers were included in an investigator-initiated, blinded, randomized, intra-individual comparison, vehicle controlled multi-centre study. Subjects were treated in a randomized manner for 3 weeks with pimecrolimus cream 1 %, mometasone furoate (1 mg/g), clobetasol propionate 0.05 % and vehicle. In addition, ultrasound examination for skin thickness was performed. Data demonstrated a direct correlation of the achieved Dermaphot® score and the ultrasound thickness measurements. Our study shows that the Dermaphot® score can be used as a simple method to evaluate the atrophogenic potential of glucocorticosteroids. Respectively, we showed that the new score is an easy, valid and sensitive new tool for early detecting and quantifying even subclinical glucocorticosteroid-induced skin damage. We demonstrated that the score is able to differentiate the extent of skin atrophy (damage) after 3 weeks of topical glucocorticosteroid application with different levels of skin transparency and levels of telangiectasia.
AB - Currently, there are no accurate and simple methods available to measure this risk of atrophy in patients treated with topical glucocorticosteroids. In the present clinical trial, we validated a new score (Dermaphot® score) to assess the atrophogenic potential of glucocorticosteroids. 36 healthy adult volunteers were included in an investigator-initiated, blinded, randomized, intra-individual comparison, vehicle controlled multi-centre study. Subjects were treated in a randomized manner for 3 weeks with pimecrolimus cream 1 %, mometasone furoate (1 mg/g), clobetasol propionate 0.05 % and vehicle. In addition, ultrasound examination for skin thickness was performed. Data demonstrated a direct correlation of the achieved Dermaphot® score and the ultrasound thickness measurements. Our study shows that the Dermaphot® score can be used as a simple method to evaluate the atrophogenic potential of glucocorticosteroids. Respectively, we showed that the new score is an easy, valid and sensitive new tool for early detecting and quantifying even subclinical glucocorticosteroid-induced skin damage. We demonstrated that the score is able to differentiate the extent of skin atrophy (damage) after 3 weeks of topical glucocorticosteroid application with different levels of skin transparency and levels of telangiectasia.
UR - http://www.scopus.com/inward/record.url?scp=84876482444&partnerID=8YFLogxK
U2 - 10.1007/s00403-012-1297-2
DO - 10.1007/s00403-012-1297-2
M3 - Journal articles
C2 - 23242470
AN - SCOPUS:84876482444
SN - 0340-3696
VL - 305
SP - 215
EP - 221
JO - Archives of Dermatological Research
JF - Archives of Dermatological Research
IS - 3
ER -